Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 246 results found. Search for [ AstraZeneca-Oxford University ]

Results 1 to 21 of 246
BusinessToday.In
November 25, 2020
Indian drug regulator may provide an emergency approval to AstraZeneca's COVID-19 vaccine by end-December or early January 21, says Nomura


BusinessToday.In
November 25, 2020
The International Air Transport Association is working on mobile app, which will act as a digital passport. The app will enclose COVID-19 test and vaccination certificates to provide a smooth travelling experience for airline passengers


BusinessToday.In
November 24, 2020
The researchers said they could not explicate why the half dose manifested better protection, but added it may be that it prompts the immune system differently


BusinessToday.In
November 24, 2020
Vardhan says it makes no sense to consider Pfizer as pharma major is yet to get approval in the US. After requisite approvals, US pharma major will have to cater to needs of its own country's population first


BusinessToday.In
November 24, 2020
Serum Institute has tied up with British-Swedish pharmaceutical firm AstraZeneca and the University of Oxford to mass-produce the Covishield vaccine to fight back COVID-19 virus


BusinessToday.In
November 24, 2020
India Stock Market Highlights Today: During the session, Sensex hit a lifetime high of 44,601 and Nifty touched record high of 13,079


BusinessToday.In
November 23, 2020
Indian Council of Medical Research is working closely with SII for Covishield vaccine trials across 15 centres in India, and would also be funding the clinical trials in the country.


BusinessToday.In
November 23, 2020
Earlier on Monday, the Oxford-AstraZeneca team announced that one of the dosing regimens of the vaccine might be 90% effective in preventing COVID-19 infection


BusinessToday.In
November 23, 2020
Vaccine can be easily manufactured, transported and stored at domestic fridge temperature (2-8 degrees C). This means it can be easily distributed using existing medical facilities such as doctor's surgeries and local pharmacies, allowing for the vaccine to be deployed very rapidly, said Oxford University


BusinessToday.In
November 23, 2020
It has been found that one of the vaccine's dosing regimens may be around 90% effective and if this dosing regime is used, more people could be vaccinated with planned vaccine supply, says AstraZeneca


BusinessToday.In
November 23, 2020
Coronavirus vaccine update: Adar Poonawalla, the CEO of Serum Institute had recently said that his company might sell a two-shot COVID-19 vaccine for around Rs 500-600 for the general public


BusinessToday.In
November 22, 2020
Bharat Biotech has started the phase- 3 trial of its potential COVID-19 vaccine, involving 26,000 volunteers this month across 25 centres in the country, including Hyderabad, Goa, Nagpur, Bhubaneswar, and Aligarh


Joe C Mathew
November 21, 2020
\"We expect emergency authorisation for Oxford-Astrazeneca vaccine to be sought in the UK. If so, it will give an opportunity for India regulator also (to consider such an option),\" says Dr Vinod Paul, chairman of the National Expert Group on Vaccine Administration for COVID-19


BusinessToday.In
November 20, 2020
Adar Poonawalla said if things go according to the plan, the coronavirus vaccine will be available for vulnerable populations by January or February. And, in March or April, the vaccine will enter the market for the general public


BusinessToday.In
November 19, 2020
Late-stage trials of the Oxford vaccine are still awaited but hopes are high that it'll also join frontrunners' league with Pfizer, Moderna and Russia's Sputnik V


BusinessToday.In
November 15, 2020
As per Anthony Fauchi, the Pfizer's vaccine distribution process in the US will start in December. This, he said, will also help reduce the daily spike in coronavirus cases, which reached 1.9 lakh this week


BusinessToday.In
November 13, 2020
Serum Institute has tied up with five developers that have made 40 million doses of the coronavirus vaccine in the past two months. They are aiming to start manufacturing of Novavax's candidate soon


PB Jayakumar
November 12, 2020
Covishield has been developed at the Serum Institute of India's Pune laboratory with a master seed from Oxford University/Astra Zeneca. The vaccine made in the UK is currently being tested in large efficacy trials in UK, Brazil, South Africa and USA


Anshula Raj
November 12, 2020
Based on the Phase 2/3 trial results, SII with the help of ICMR will pursue the early availability of this product for India


Reuters
November 11, 2020
Scientists, public health officials and investors welcomed the first successful interim data from a large-scale clinical test as a watershed moment that could help turn the tide of the pandemic if the full trial results pan out


PAGES 1 OF 13  12345